
|Articles|September 25, 2014
- Gynecologic Cancers (Issue 1)
- Volume 1
- Issue 1
The Role of Molecular Testing in Gynecologic Cancers
Author(s)Maurie Markman, MD
Maurie Markman, MD, discusses the role of molecular testing in gynecologic cancers.
Advertisement
Maurie Markman, MD, senior vice president for Clinical Affairs and National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses the role of molecular testing in gynecologic cancers.
View more about screening for ovarian cancer > >
Articles in this issue
about 11 years ago
Trabectedin as a Treatment Option for Patients with Ovarian Cancerabout 11 years ago
Dream Team Aims To Change the Face of Ovarian Cancer Researchabout 11 years ago
On The Horizon for Ovarian Cancer: Potentially Promising Treatmentsabout 11 years ago
Cediranib Versus Olaparib in Recurrent Platinum-Sensitive Ovarian CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5









































